Structure and biological properties of five Pt(II) complexes as potential anticancer agents
作者:Jungang Deng、Jun Wang、MuhammadHamid Khan、Ping Yu、Feng Yang、Hong Liang
DOI:10.1016/j.jinorgbio.2018.04.017
日期:2018.8
and validated five Schiff base Pt(II) complexes derived from 2-hydroxy-1-naphthaldehyde benzoyl hydrazone and its derivatives, which are modified at the benzohydrazide structures (L1–L5). The complexes were [Pt(L1)(DMSO)Cl] (C1), [Pt(L2)(DMSO)Cl] (C2), [Pt(L3)(DMSO)Cl] (C3), [Pt(L4)(DMSO)Cl] (C4), and [Pt(L5)(DMSO)Cl] (C5). Crystal structures showed that the Pt centers of all complexes were tetra-coordinated
我们合成并验证了5种衍生自2-羟基-1-萘醛苯甲酰及其衍生物的席夫碱Pt(II)配合物,这些配合物在苯并酰肼结构上被修饰(L1-L5)。络合物为[Pt(L1)(DMSO)Cl](C1),[Pt(L2)(DMSO)Cl](C2),[Pt(L3)(DMSO)Cl](C3),[Pt(L4) (DMSO)Cl](C4)和[Pt(L5)(DMSO)Cl](C5)。晶体结构表明,所有配合物的Pt中心都与其他原子四配位。探索了复合物的构效关系和抗癌机理。这五种Pt(II)复合物在微摩尔剂量下均具有毒性,并显示出与IC 50相似或略高于顺铂的细胞毒性。值范围从4.38μM到25.16μM。该复合物通过靶向c-myc启动子并下调人端粒酶逆转录酶的表达来抑制端粒酶发挥化学治疗作用,从而触发细胞凋亡。此外,Pt(II)复合物还导致细胞周期停滞在S期,导致cdc25 A,cyclin A2和CDK2的下调以及p5